Idiopathic interstitial pneumonia (IIP) entails a variable group of lung diseases of unknown etiology. Idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, interstitial lung diseases related to connective tissue disease (CTD-ILD), and hypersensitivity pneumonitis (HP) can manifest with similar clinical, radiological, and histopathological features. In a differential diagnosis, biomarkers can play a significant role. We assume that levels of specific cyto- or chemokines or their receptors can signal pathogenetic processes in the lungs. Eighty patients with different types of idiopathic interstitial pneumonia were enrolled in this study. Cell counts and concentrations of tumor necrosis factor (TNF)-α, interleukin-4 receptor α, proteinase-activated receptor (PAR)-2, matrix metalloproteinase (MMP)-7, and B cell-activating factor were measured in bronchoalveolar lavage fluid using commercial ELISA kits. High resolution computer tomography results were evaluated using alveolar and interstitial (IS) score scales. Levels of TNF-α were significantly higher in HP compared to fibrosing IIP (p < 0.0001) and CTD-ILD (p = 0.0381). Concentrations of IL-4Rα, PAR-2, and MMP-7 were positively correlated with IS (p = 0.0009; p = 0.0256; p = 0.0015, respectively). Since TNF-α plays a major role in inflammation, our results suggest that HP is predominantly an inflammatory disease. From the positive correlation with IS we believe that IL-4Rα, PAR-2, and MMP-7 could serve as fibroproliferative biomarkers in differential diagnosis of IIP.

Department of Pathology 1st Faculty of Medicine Charles University and General University Hospital Studnickova 2 128 00 Prague Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University and University Hospital Kralovske Vinohrady Srobarova 1150 50 100 34 Prague Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University and Thomayer University Hospital Videnska 800 140 59 Prague Czech Republic

Department of Respiratory Medicine 1st Faculty of Medicine Charles University and Thomayer University Hospital Videnska 800 140 59 Prague Czech Republic

Department of Respiratory Medicine University Hospital Pilsen Edvarda Benese 1128 13 305 99 Pilsen Czech Republic

Zobrazit více v PubMed

Silva C.I.S., Müller N.L. Idiopathic interstitial pneumonias. J. Thorac. Imaging. 2009;24:260–273. doi: 10.1097/RTI.0b013e3181c1a9eb. PubMed DOI

Morais A., Beltrão M., Sokhatska O., Costa D., Melo N., Mota P.C., Marques A., Delgado L. Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias. Respir. Med. 2015;109:1063–1068. doi: 10.1016/j.rmed.2015.06.003. PubMed DOI

Nayfeh A.S., Chippa V., Moore D.R. Nonspecific Interstitial Pneumonitis. StatPearls Publishing LLC; Treasure Island, FL, USA: 2020. PubMed

Koo S.M., Uh S.T. Treatment of connective tissue disease-associated interstitial lung disease: The pulmonologist’s point of view. Korean J. Intern. Med. 2017;32:600–610. doi: 10.3904/kjim.2016.212. PubMed DOI PMC

Raghu G., Remy-Jardin M., Ryerson C.J., Myers J.L., Kreuter M., Vasakova M., Bargagli E., Chung J.H., Collins B.F., Bendstrup E., et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2020;202:e36–e69. doi: 10.1164/rccm.202005-2032ST. PubMed DOI PMC

Riario Sforza G.G., Marinou A. Hypersensitivity pneumonitis: A complex lung disease. Clin. Mol. Allergy. 2017;15:1–8. doi: 10.1186/s12948-017-0062-7. PubMed DOI PMC

Smith M., Dalurzo M., Panse P., Parish J., Leslie K. Usual interstitial pneumonia-pattern fibrosis in surgical lung biopsies. Clinical, radi-ological and histopathological clues to aetiology. J. Clin. Pathol. 2013;66:896–903. doi: 10.1136/jclinpath-2013-201442. PubMed DOI PMC

Rosas I.O., Richards T.J., Konishi K., Zhang Y., Gibson K., Lokshin A.E., Lindell K.O., Cisneros J., MacDonald S.D., Pardo A., et al. MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis. PLoS Med. 2008;5:e93. doi: 10.1371/journal.pmed.0050093. PubMed DOI PMC

Bauer Y., White E.S., De Bernard S., Cornelisse P., Leconte I., Morganti A., Roux S., Nayler O. MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2017;3:74–2016. doi: 10.1183/23120541.00074-2016. PubMed DOI PMC

Piguet P.F., Ribaux C., Karpuz V., Grau G.E., Kapanci Y. Expression and localization of tumor necrosis factor-α and its mRNA in idiopathic pulmonary fibrosis. Am. J. Pathol. 1993;143:651–655. PubMed PMC

Distler J.H.W., Schett G., Gay S., Distler O. The controversial role of tumor necrosis factor α in fibrotic diseases. Arthritis Rheumatol. 2008;58:2228–2235. doi: 10.1002/art.23645. PubMed DOI

Chen B., Tong Z., Nakamura S., Costabel U., Guzman J. Production of IL-12, IL-18 and TNF-alpha by alveolar macrophages in hypersensitivity pneumonitis. Sarcoidosis Vasc. Diffus. Lung Dis. 2004;21:199–203. PubMed

Vuorinen K., Myllärniemi M., Lammi L., Piirilä P., Rytilä P., Salmenkivi K., Kinnula V.L. Elevated matrilysin levels in bronchoalveolar lavage fluid do not distinguish idiopathic pulmonary fibrosis from other interstitial lung diseases. APMIS. 2007;115:969–975. doi: 10.1111/j.1600-0463.2007.apm_697.x. PubMed DOI

Wygrecka M., Kwapiszewska G., Jablonska E., Von Gerlach S., Henneke I., Zakrzewicz D., Guenther A., Preissner K.T., Markart P. Role of Protease-activated Receptor-2 in Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2011;183:1703–1714. doi: 10.1164/rccm.201009-1479OC. PubMed DOI

Fujita M., Shannon J.M., Morikawa O., Gauldie J., Hara N., Mason R.J. Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta. Am. J. Respir. Cell Mol. Biol. 2003;29:669–676. doi: 10.1165/rcmb.2002-0046OC. PubMed DOI

Byrne A.J., Maher T.M., Lloyd C.M. Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease? Trends Mol. Med. 2016;22:303–316. doi: 10.1016/j.molmed.2016.02.004. PubMed DOI

Liu G., Zhai H., Zhang T., Li S., Li N., Chen J., Gu M., Qin Z., Liu X. New therapeutic strategies for IPF: Based on the “phagocytosis-secretion-immunization” network regulation mechanism of pulmonary macrophages. Biomed. Pharmacother. 2019;118:109230. doi: 10.1016/j.biopha.2019.109230. PubMed DOI

Vasakova M., Sterclova M., Stranska E., Mandakova P., Skibova J., Matej R. Biomarkers of Fibroproliferative Healing in Fibrosing Idiopathic Interstitial Pneumonias. Open Respir. Med. J. 2012;6:160–164. doi: 10.2174/1874306401206010160. PubMed DOI PMC

Parameswaran N., Patial S. Tumor Necrosis Factor-α Signaling in Macrophages Narayanan. Adv. Glob. Chang. Res. 2010;20:87–103. PubMed PMC

Nhu Q.M., Shirey K.A., Pennini M.E., Stiltz J., Vogel S.N. Proteinase-activated receptor 2 activation promotes an anti-inflammatory and alternatively activated phenotype in LPS-stimulated murine macrophages. Innate Immun. 2011;18:193–203. doi: 10.1177/1753425910395044. PubMed DOI PMC

Steven R., Crilly A., Lockhart J.C., Ferrell W.R., McInnes I.B., Islam M.A., Pröll M., Hölker M., Tholen E., Tesfaye D., et al. Proteinase-activated receptor-2 modulates human macrophage differentiation and effector function. Innate Immun. 2013;19:663–672. doi: 10.1177/1753425913479984. PubMed DOI

Craig V.J., Zhang L., Hagood J.S., Owen C.A. Matrix Metalloproteinases as Therapeutic Targets for Idiopathic Pulmonary Fibrosis. Am. J. Respir. Cell Mol. Biol. 2015;53:585–600. doi: 10.1165/rcmb.2015-0020TR. PubMed DOI PMC

Fujishima S., Shiomi T., Yamashita S., Yogo Y., Nakano Y., Inoue T., Nakamura M., Tasaka S., Hasegawa N., Aikawa N., et al. Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis. Arch. Pathol. Lab. Med. 2010;134:1136–1142. doi: 10.5858/2009-0144-OA.1. PubMed DOI

Zuo F., Kaminski N., Eugui E., Allard J., Yakhini Z., Ben-Dor A., Lollini L., Morris D., Kim Y., DeLustro B., et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc. Natl. Acad. Sci. USA. 2002;99:6292–6297. doi: 10.1073/pnas.092134099. PubMed DOI PMC

Tzouvelekis A., Herazo-Maya J.D., Slade M., Chu J.-H., Deiuliis G., Ryu C., Li Q., Sakamoto K., Ibarra G., Pan H., et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology. 2017;22:486–493. doi: 10.1111/resp.12920. PubMed DOI PMC

Ng L.G., Sutherland A.P.R., Newton R., Qian F., Cachero T.G., Scott M.L., Thompson J.S., Wheway J., Chtanova T., Groom J., et al. B Cell-Activating Factor Belonging to the TNF Family (BAFF)-R Is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells. J. Immunol. 2004;173:807–817. doi: 10.4049/jimmunol.173.2.807. PubMed DOI

Xue J., Kass D.J., Bon J., Vuga L., Tan J., Csizmadia E., Otterbein L., Soejima M., Levesque M.C., Gibson K.F., et al. Plasma B Lymphocyte Stimulator and B Cell Differentiation in Idiopathic Pulmonary Fibrosis Patients. J. Immunol. 2013;191:2089–2095. doi: 10.4049/jimmunol.1203476. PubMed DOI PMC

Raghu G., Remy-Jardin M., Myers J.L., Richeldi L., Ryerson C.J., Lederer D.J., Behr J., Cottin V., Danoff S.K., Morell F., et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2018;198:e44–e68. doi: 10.1164/rccm.201807-1255ST. PubMed DOI

Gay S.E., Kazerooni E.A., Toews G.B., Lynch J.P., III, Gross B.H., Cascade P.N., Spizarny D.L., Flint A., Schork M.A., Whyte R.I., et al. Idiopathic pulmonary fibrosis: Predicting response to therapy and survival. Am. J. Respir. Crit. Care Med. 1998;157:1063–1072. doi: 10.1164/ajrccm.157.4.9703022. PubMed DOI

Vasakova M., Stříž I., Dutka J., Slavcev A., Jandova S., Kolesar L., Šulc J. Cytokine gene polymorphisms and high-resolution-computed tomography score in idiopathic pulmonary fibrosis. Respir. Med. 2007;101:944–950. doi: 10.1016/j.rmed.2006.09.013. PubMed DOI

Meyer K.C., Raghu G., Baughman R.P., Brown K.K., Costabel U., du Bois R.M., Drent M., Haslam P.L., Kim D.S., Nagai S., et al. An official American Thoracic Society clinical practice guideline: The clinical utility of bron-choalveolar lavage cellular analysis in interstitial lung disease. Am. J. Respir. Crit. Care Med. 2012;185:1004–1014. doi: 10.1164/rccm.201202-0320ST. PubMed DOI

Meyer K.C., Raghu G. Bronchoalveolar lavage for the evaluation of interstitial lung disease: Is it clinically useful? Eur. Respir. J. 2011;38:761–769. doi: 10.1183/09031936.00069509. PubMed DOI

King T.E., Jr. Role of Bronchoalveolar Lavage in Diagnosis of Interstitial Lung Disease. [(accessed on 10 April 2020)];2019 Available online: uptodate.com.

Pantelidis P., Fanning G.C., Wells A.U., Welsh K.I., Du Bois R.M. Analysis of Tumor Necrosis Factor- α, Lymphotoxin- α, Tumor Necrosis Factor Receptor II, and Interleukin-6 Polymorphisms in Patients with Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2001;163:1432–1436. doi: 10.1164/ajrccm.163.6.2006064. PubMed DOI

Armstrong L., Godinho S.I.H., Uppington K.M., Whittington H.A., Millar A.B. Tumour necrosis factor-α processing in interstitial lung disease: A potential role for exogenous proteinase-3. Clin. Exp. Immunol. 2009;156:336–343. doi: 10.1111/j.1365-2249.2009.03906.x. PubMed DOI PMC

Park Y.S., Park C.M., Lee H.J., Goo J.M., Chung O.H., Lee S.-M., Yim J.-J., Kim Y.W., Han S.K., Yoo C.-G. Clinical implication of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Respir. Med. 2013;107:256–262. doi: 10.1016/j.rmed.2012.10.011. PubMed DOI

Samara K., Giannarakis I., Papanikoalou I., Lambiri I., Siafakas N., Antoniou K. Overexpression of matrix metalloproteinase-7 (MMP-7) in bronchoalveolar lavage fluid (BALF) of IPF and lung cancer patients. Eur. Respir. J. 2011;38:4761.

Hu G., Christman J.W. Editorial: Alveolar macrophages in lung inflammation and resolution. Front Immunol. 2019;10:2275. doi: 10.3389/fimmu.2019.02275. PubMed DOI PMC

Misharin A.V., Morales-Nebreda L., Mutlu G.M., Budinger G.R.S., Perlman H. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am. J. Respir. Cell Mol. Biol. 2013;49:503–510. doi: 10.1165/rcmb.2013-0086MA. PubMed DOI PMC

Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:445–455. doi: 10.1038/nature12034. PubMed DOI PMC

Drakopanagiotakis F., Xifteri A., Tsiambas E., Karameris A., Tsakanika K., Karagiannidis N., Mermigkis D., Polychronopoulos V., Bouros D. Decreased Apoptotic Rate of Alveolar Macrophages of Patients with Idiopathic Pulmonary Fibrosis. Pulm. Med. 2012;2012:1–9. doi: 10.1155/2012/981730. PubMed DOI PMC

Miyazaki Y., Araki K., Vesin C., Garcia I., Kapanci Y., Whitsett J.A., Piguet P.F., Vassalli P. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J. Clin. Investig. 1995;96:250–259. doi: 10.1172/JCI118029. PubMed DOI PMC

Kolbeková M., Šterclová M., Smětáková M., Skibova J., Vašáková M. The role of matrix metalloproteinase 7 in pathogenesis of interstitial lung diseases on the background of connective tissue diseases. Alergie. 2016;4:217–223.

Sterclova M., Matej R., Mandakova P., Skibova J., Vasakova M. Role of interleukin 4 and its receptor in clinical presentation of chronic extrinsic allergic alveolitis: A pilot study. Multidiscip. Respir. Med. 2013;8:35. doi: 10.1186/2049-6958-8-35. PubMed DOI PMC

Huh J.W., Kim D.S., Oh Y.-M., Shim T.S., Lim C.M., Lee S.D., Koh Y., Kim W.S., Kim W.D., Kim K.R. Is Metalloproteinase-7 Specific for Idiopathic Pulmonary Fibrosis? Chest. 2008;133:1101–1106. doi: 10.1378/chest.07-2116. PubMed DOI

Matěj R., Smětáková M., Vašáková M., Nováková J., Šterclová M., Kukal J., Olejár T. PAR-2, IL-4R, TGF-β and TNF-α in bronchoalveolar lavage distinguishes extrinsic allergic alveolitis from sarcoidosis. Exp. Ther. Med. 2014;8:533–538. doi: 10.3892/etm.2014.1776. PubMed DOI PMC

Oasis Pharmaceuticals, LLC . PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis. Oasis Pharmaceuticals, LLC; Lexington, MA, USA: 2017.

Francois A., Schneider P., Davidson A., Chatelus E., Avouac J., Allanore Y., Villeret B., Gombault A., Gasse P., Adam S.M. A new pathogenic role of BAFF as a critical mediator of skin and lung fibrosis in experimental bleomycin-induced pulmonary fibrosis, systemic sclerosis and idiopathic pulmonary fibrosis. Arthritis Rheumatol. 2013;65:2610.

François A., Gombault A., Villeret B., Alsaleh G., Fanny M., Gasse P., Adam S.M., Crestani B., Sibilia J., Schneider P., et al. B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis. J. Autoimmun. 2015;56:1–11. doi: 10.1016/j.jaut.2014.08.003. PubMed DOI

Fanny M., Gombault A., François F., Villeret B., Ryffel B., Wachhsmann D., Gottenberg J.-E., Couillin I. B-cell activating factor regulates IL-1β- and IL-17A-mediated pulmonary fibrosis in mice. Rev. Mal. Respir. 2015;32:311. doi: 10.1016/j.rmr.2015.02.021. DOI

Hamada T., Samukawa T., Kumamoto T., Hatanaka K., Tsukuya G., Yamamoto M., Machida K., Watanabe M., Mizuno K., Higashimoto I., et al. Serum B cell–activating factor (BAFF) level in connective tissue disease associated interstitial lung disease. BMC Pulm. Med. 2015;15:1–8. doi: 10.1186/s12890-015-0105-0. PubMed DOI PMC

Zhao Y.Y., Lian H.J., Li S., Fang C.L., Huang H., Xu Z.J. The role of B cell activating factor in the differential diagnosis of usual interstitial pneumonia. Chin. J. Tuberc. Respir. Dis. 2018;41:544–550. PubMed

Prele C., Lucas A., Barrett L., Baltic S., Fear M., Knight D., Laurent G., Mcanulty R., Mutsaers S., Hoyne G. Characterisation of b cell subsets in the blood and lung of patients with idiopathic pulmonary fibrosis. TSANZ Poster Present. 2018;23:186.

Vasakova M., Sterclova M., Kolesár L., Slavcev A., Pohunek P., Sulc J., Skibová J., Striz I. Bronchoalveolar Lavage Fluid Cellular Characteristics, Functional Parameters and Cytokine and Chemokine Levels in Interstitial Lung Diseases. Scand. J. Immunol. 2009;69:268–274. doi: 10.1111/j.1365-3083.2008.02222.x. PubMed DOI

Jakubzick C., Choi E.S., Kunkel S.L., Evanoff H., Martinez F.J., Puri R.K., Flaherty K.R., Toews G.B., Colby T.V., Kazerooni E.A., et al. Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia. J. Clin. Pathol. 2004;57:477–486. doi: 10.1136/jcp.2003.012799. PubMed DOI PMC

Vasakova M., Striz I., Slavcev A., Jandova S., Kolesár L., Sulc J. Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. Tissue Antigens. 2006;67:229–232. doi: 10.1111/j.1399-0039.2006.00560.x. PubMed DOI